{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+COVID-19&page=2", "query": { "condition": "Mild to Moderate COVID-19", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+COVID-19&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T16:08:28.428Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05164120", "title": "Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Belnacasan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedStar Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-12-14", "completion_date": "2022-10-11", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-07-24T16:08:28.428Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05164120" }, { "nct_id": "NCT05941793", "title": "A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mild to Moderate COVID-19" ], "interventions": [ { "name": "MBS-COV", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oneness Biotech Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2023-09-11", "completion_date": "2024-08-12", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-07-24T16:08:28.428Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05941793" }, { "nct_id": "NCT04427501", "title": "A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "LY3819253", "type": "DRUG" }, { "name": "LY3832479", "type": "DRUG" }, { "name": "LY3853113", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": null, "sex": "ALL", "summary": "0 Years and older" }, "enrollment_count": 3307, "start_date": "2020-06-17", "completion_date": "2023-02-21", "has_results": true, "last_update_posted_date": "2024-04-11", "last_synced_at": "2026-07-24T16:08:28.428Z", "location_count": 12, "location_summary": "Redondo Beach, California • Miami, Florida • Union City, Georgia + 9 more", "locations": [ { "city": "Redondo Beach", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Union City", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04427501" }, { "nct_id": "NCT04600895", "title": "The Prevent Severe COVID-19 (PRESECO) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Favipiravir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Appili Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1187, "start_date": "2020-11-30", "completion_date": "2021-10-20", "has_results": true, "last_update_posted_date": "2024-03-29", "last_synced_at": "2026-07-24T16:08:28.428Z", "location_count": 25, "location_summary": "Pelham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 14 more", "locations": [ { "city": "Pelham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04600895" }, { "nct_id": "NCT04634409", "title": "A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Bamlanivimab", "type": "DRUG" }, { "name": "Etesevimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "VIR-7831", "type": "DRUG" }, { "name": "Bebtelovimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1755, "start_date": "2020-10-29", "completion_date": "2021-10-18", "has_results": true, "last_update_posted_date": "2022-07-01", "last_synced_at": "2026-07-24T16:08:28.428Z", "location_count": 127, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 103 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City West", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634409" }, { "nct_id": "NCT04399356", "title": "Niclosamide for Mild to Moderate COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Niclosamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Telehealth monitoring", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2020-10-01", "completion_date": "2021-08-19", "has_results": true, "last_update_posted_date": "2022-04-12", "last_synced_at": "2026-07-24T16:08:28.428Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04399356" }, { "nct_id": "NCT04880109", "title": "A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "APX-115", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aptabio Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2021-10-20", "completion_date": "2022-04-28", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-07-24T16:08:28.428Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Annapolis, Maryland • Wyoming, Michigan + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Annapolis", "state": "Maryland" }, { "city": "Wyoming", "state": "Michigan" }, { "city": "Jamaica", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04880109" }, { "nct_id": "NCT04701658", "title": "A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Bamlanivimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 109, "start_date": "2021-02-01", "completion_date": "2021-06-22", "has_results": true, "last_update_posted_date": "2021-11-16", "last_synced_at": "2026-07-24T16:08:28.428Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT04701658" }, { "nct_id": "NCT04486313", "title": "Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Vitamin Super B-Complex", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Romark Laboratories L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 935, "start_date": "2020-08-13", "completion_date": "2021-02-08", "has_results": true, "last_update_posted_date": "2024-03-29", "last_synced_at": "2026-07-24T16:08:28.428Z", "location_count": 2, "location_summary": "Fort Lauderdale, Florida • The Bronx, New York", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04486313" }, { "nct_id": "NCT04504734", "title": "Bucillamine in Treatment of Patients With COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Bucillamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revive Therapeutics, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 713, "start_date": "2020-11-27", "completion_date": "2023-06-12", "has_results": false, "last_update_posted_date": "2023-07-07", "last_synced_at": "2026-07-24T16:08:28.428Z", "location_count": 46, "location_summary": "Cullman, Alabama • Huntsville, Alabama • Phoenix, Arizona + 38 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04504734" } ] }